Core 3

DF/HCC前列腺癌孢子组织和病理核心已经提供并将继续提供 合作研究人员提供多种病理服务，包括组织学、免疫组织化学、原位 杂交、荧光原位杂交、计算机辅助图像分析、激光捕获 显微解剖，以及组织微阵列(TMA)的产生和获取。我们的首要目标是 在Dana之间广泛的现有组织资源之间建立无缝的信息链接- 法伯/哈佛癌症中心(DF/HCC)医院和合作者。因此，这一行动的主要目标之一 核心是维持和生长现有的组织和血液资源(以下称为“生物库”)， 链接到临床结果数据，支持可供DF/HCC使用的安全数据管理系统 孢子调查员以及其他机构的孢子调查员。在这方面，有并将会有 继续在组织和病理核心与生物统计学和 计算生物学核心。 该核心的指导原则现已列出： 1)成功的翻译研究需要广泛的注释良好的人类分析物，小鼠 模型、异种移植和细胞系。 2)患者保护和监管问题是任何生物库的首要任务。 3)需要在执行之前确定对样本和使用规则(治理)的访问 实验。 4)每个样本产生的数据增加了该样本的价值。 5)生物库应促进有资格的调查人员的研究，无论他们隶属于 DF/HCC前列腺癌孢子(即，鼓励来自世界各地的优秀研究 世界)。 6)应监测样品的分析前可变性和标准操作程序(SOP) 应该在知道的情况下使用。 7)与预先存在的计划的协同可以节省工作量。 8)在资源有限的情况下，生物库应首先侧重于五个孢子项目和 发展项目和职业发展奖获得者的项目。 9)生物信息学加强了对生物库样本产生的数据的使用。

The DF/HCC Prostate Cancer SPORE Tissue and Pathology Core has provided and will continue to provide collaborating investigators multiple pathology services including histology, immunohistochemistry, in situ hybridization, fluorescent in situ hybridization (FISH), computer-assisted image analysis, laser capture microdissection, and the generation of and access to tissue microarrays (TMAs). Our overarching goal is to create a seamless informatics link between the extensive existing tissue resources among the Dana- Farber/Harvard Cancer Center (DF/HCC) hospitals and collaborators. Thus, one of the major goals of this Core is to maintain and grow an existing tissue and blood resource (henceforth referred to as "biobank"), linked to clinical outcome data, behind a secure data management system that will be available to DF/HCC SPORE investigators as well as SPORE investigators at other institutions. In this regard there is and will continue to be close collaboration between the Tissue and Pathology Core and the Biostatistical and Computational Biology Core. The guiding principles of this Core are now listed: 1) Successful translational research requires a wide range of well-annotated human analytes, mouse models, xenografts, and cell lines. 2) Patient protection and regulatory issues are the top priority of any biobank. 3) Access to samples and rules of usage (governance) need to- be determined prior to performing experiments. 4) Data generated from each sample increase that sample's value. 5) The biobank should facilitate research of qualified investigators regardless of their affiliation to the DF/HCC Prostate Cancer SPORE (i.e., outstanding research is encouraged from all corners of the world). 6) Pre-analytic variability of samples should be monitored and standard operating procedures (SOPs) should be employed when known. 7) Synergy with pre-existing programs leads to economy of effort. 8) Given limited resources, the biobank should focus first on the five SPORE Projects and the Developmental Projects and Projects of the Career Development Awardees. 9) Bioinformatics enhances the use of data generated from biobank samples.